Propofol EDTA and reduced incidence of infection.
Propofol formulated in a lipid vehicle supports the growth of microorganisms. There have been worldwide reports of extrinsic microbial contamination of propofol leading to outbreaks of serious postoperative nosocomial infections. Therefore it is essential that medical professionals follow strict aseptic precautions when handling propofol, as recommended by manufacturers of propofol and the Centers for Disease Control and Prevention. Non-adherence to these recommendations increases the risk of nosocomial postoperative infections, which impose a heavy burden of morbidity and mortality and have serious economic consequences. It has also been recommended that the use of EDTA-containing formulations of propofol be considered. In vitro studies have confirmed that EDTA added to propofol retards microbial growth. Data on the incidence of nosocomial infections before and after the introduction of propofol with EDTA indicates that there have been no further cluster outbreaks and individual nosocomial infections appear to have been reduced. The addition of EDTA is an additional safety precaution to good aseptic practice.
Jansson
J R
JR
Medical Neuroscience, AstraZeneca R&D, Sodertalje, Sweden.
Fukada
T
T
Ozaki
M
M
Kimura
S
S
D018686:Anesthetics, Intravenous; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000254:growth & development; D003428:Cross Infection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004340:Drug Contamination / Q000517:prevention & control*; D004492:Edetic Acid / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D015742:Propofol / Q000008:administration & dosage*; D014481:United States / Q000453:epidemiology
D018686:Anesthetics, Intravenous; D000890:Anti-Infective Agents; D004492:Edetic Acid; D015742:Propofol